PC-SPES is a botanically based dietary supplement that has been used by men following prostate cancer treatment to reduce prostate-specific antigen levels. It is a complex matrix comprising 8 herbs whose known chemistry and biology do not account for the observed clinical activity. Recent disclosures have forced the product to be withdrawn from the market. Aspects of previous scientific research on the product, including clinical information, are reviewed, and some suggestions are offered for the future scientific needs of this product. Some thoughts are also offered on what the recall of PC-SPES means for the future scientific directions of the dietary supplement industry.
In recent years, a number of botanically based dietary supplements have been introduced into commerce and have become popular as alternative therapies to prescription and over-the-counter drugs. Most of these products have been introduced as palliatives and preventative agents, with the notion that the diverse, deleterious aspects of aging on the human condition can be delayed, or in some way ameliorated. Rarely has a product been introduced specifically to produce a therapeutic effect in a disease state, and it is rarer indeed for a product to be made available for the delicate area of cancer chemotherapy. In this context, the product known as PC-SPES stands out as unusual. This article will offer a partial review of some of the salient features relating to background, botanical aspects, chemical constituents, in vitro and in vivo biology, and clinical aspects of this product. In considering this product, it is important to realize that it was sold primarily through Internet commerce and to a lesser extent in selective retail markets. Before discussing this product, some background in the regulation of dietary supplement regulation and on the scientific aspects of pharmacognosy that apply to dietary supplements is pertinent.
Botanically based dietary supplements are regulated by the U.S. Food and Drug Administration (FDA) through the Dietary Supplement Health and Safety Act (DSHEA) of 1994. This act relates to the control of the labeling on the product and to the accuracy of the description (genus and species) of the plant material(s) contained. The DSHEA does not require that the material be botanically authenticated, nor does it require a presentation of the relative content of the respective plant materials if more than 1 is present. No medical claims are allowed that would relate to any amelioration of, or prevention of, a disease state or the symptoms thereof. In January 2000, the FDA issued final regulations with regard to the structure/function claims and the naming of dietary supplements, 1 and offered examples of allowed conditions for which claims could be made and disallowed conditions for which claims could not be made. In doing so, the FDA resorted to an existing definition of disease. The FDA did not believe that the rule was a site to address substantiation of claims. 2 Thus, the DSHEA and its regulations have no requirement for the demonstration of efficacy, for demonstrating the absence of toxicity, or for demonstrating the absence of adulterants, heavy metals, pesticides, radiation, and so on. The DSHEA has no requirement for batch-tobatch consistency of the botanical material(s), of the chemical profile, of the biological activities, of the relationship of a biological activity to a disease, or of the stability and shelf-life of the product. Because of the absence of these requirements, companies marketing these products do not usually take the necessary steps to ensure that such concerns are either studied from a research perspective or monitored on a continuous basis. Consumers are therefore very much on their own in assessing a particular product, without any assurance of federal control over its safety and efficacy. In the case of the product PC-SPES, this background is particularly relevant because, as discussed subsequently, PC-SPES comprises a complex matrix of 8 plant materials, and was found to be adulterated and subsequently withdrawn.
The history of using plant materials for the amelioration of the cancerous state is as old as the written history of the use of plants as medicinal agents. Hartwell, whose pioneering work on a Native American remedy, the mayapple, 3 led to 2 anticancer drugs, etoposide and teniposide, also compiled the amazing work "Plants Used Against Cancer: A Survey," which was published as a series in the journal Lloydia and subsequently as a book. 4 This work was recently supplemented by Farnsworth and colleagues. 5 In this compilation, the history of the use of plants by indigenous groups throughout the world for the treatment of cancer is catalogued by plant family. Thus, the use of plants is well established, and indeed several compounds (camptothecin, paclitaxel, vinblastine, vincristine) derived from plants are currently a part of the allopathic chemotherapeutic armamentarium for cancer. 6 Additional compounds derived from plants are approved for use in other parts of the world.
In the past few years, it has become apparent that cancer patients are actively seeking complementary/ alternative approaches to serve either adjunctively with allopathic chemotherapy or singly as a replacement for primary therapy. In a recent study assessing the prevalence of complementary and alternative medicine (CAM) in a comprehensive cancer center, 83.3% of patients had used at least 1 CAM approach and 62.6% had used vitamins and herbs. 7 Prostate cancer is a burgeoning medical problem, particularly in Western countries and more succinctly in the African American male population. 8 Each year in the United States approximately 180,000 new cases are diagnosed with about 30,000 deaths from the disease or its further dissemination. 9, 10 The incidence rates vary substantially across the world. The highest incidence rate globally is for U.S. African Americans (137/100,000). In Europe and South America, the rate was 20-50/100,000, and in Shanghai, China, the rate was 2.3/100,000. Similar low incidence rates are observed for populations in Japan, Korea, and the Philippines. 8 The relationship between genetic and environmental factors, such as diet, on these incidence levels is not clear at the present time.
The development of a test for prostate-specific antigen (PSA) substantially aided the detection of prostate cancer and permitted the timely, aggressive treatment of the disease through prostatectomy, cryotherapy, radiation, and/or chemotherapy. 11 However, the cancerous state frequently becomes refractory to treatment with hormones, thereby leading to further metastases and eventually death. Indeed, patients with hormone refractory prostate cancer have a median survival of 6 to 12 months, 12 and current regimens show only modest efficacy and no increase in patient survival time. 12 As a result, CAM regimens are being actively employed as strategies to modulate the metastatic process. 13, 14 One such approach is the use of the product PC-SPES. 15 Most of the plant materials being used as adjuncts in CAM therapy for cancer are single species of higher and lower plants (green tea, rye bran, astragalus root, garlic bulb, reishi, maitake, etc). PC-SPES, however, is a complex mixture of 8 plant materials recently formulated by 3 Taiwanese scientists: S. Chen, A. Wang, and H.-F. Wang.
First developed in Taiwan in 1990, PC-SPES was brought to the United States in 1994. It is a product of BotanicLab Inc. in Brea, California, and it became the most popular product in the alternative medicine community as a treatment for prostate cancer. The name of the product is derived from "prostate cancer" and spes, the Latin word for "hope." Until the recent withdrawal of the product, PC-SPES was made available on the Internet through the site www.botaniclab.org.
The product comprises 8 plant materials, which are "processed and refined according to proprietary technology." The plant materials and the parts employed, as they are described in the company literature, are Although the total dose of the plant matrix is given (320 mg), it is important to note that the specific ratio of these 8 plant materials in the product is not disclosed. Whether the material contained in the capsules is crude plant material, an extract of the indicated plant, or a semipurified extract of the material is also not indicated on the package, in the company literature, or on the Web site.
Several claims have been made by the inventors with regard to the specific actions of the component plant materials. Included in these claims are that quercetin (in G. glabra) has antitumor effects, that Glycyrrhiza lowers serum cholesterol levels, and that G. lucidum inhibits sarcoma 180 in mice and Lewis lung carcinoma in mice with a prolongation in life span of 195%. It is also claimed that R. rubescens inhibits the growth of HeLa cells, Ehrlich ascites cells, sarcoma 180 cells, hepatoma cells, cervical carcinoma U14 cells, Walker 256 carcinosarcoma cells, and reticular carcinoma cells, and that S. repens decreases bioavailability of testosterone (5-α-reductase inhibition). Ten "properties" of PC-SPES are described: (1) neutralizes free radicals through antioxidant action, (2) lowers or raises the red blood cell count depending on need, (3) lowers or raises the white blood cell count depending on need, (4) is nontoxic, (5) has distinct antitoxic action against a wide range of toxins, (6) induces cancer cell death, (7) is good for the central nervous system, (8) suppresses the cancer gene bcl-2, (9) suppresses androgen receptor growth, and (10) changes the cancer cell growth cycle. In addition, a number of potential benefits of PC-SPES are projected: (1) prevents or delays the recurrence of prostate cancer; (2) lengthens the survival time of prostate cancer patients by reducing the dosage of combination hormone therapy; (3) improves the effectiveness of conventional treatments; (4) delays the use of chemotherapy; (5) decreases tumor burden, thereby inhibiting the growth of prostate cancer; (6) is an adjunct treatment for combination hormone therapy (CHT); (7) is an alternative treatment when CHT is no longer effective; (8) serves as an effective dietary supplement used to maintain a patient on deferred treatment; (9) prolongs a patient's stay on intermittent CHT; and (10) acts as an effective adjunct treatment either before, during, or after conventional treatment.
It is claimed that PC-SPES works because it A number of previous reviews of PC-SPES are available. [16] [17] [18] [19] [20] [21] [22] [23] Darzynkiewicz et al 17 (including one of the founders of BotanicLab, S. Chen) have provided the most detailed review to date, including a discussion of some aspects of the previous work on the constituent plants, the clinical observations to date, the in vitro and in vivo effects of PC-SPES, and some suggestions for future directions. The review by DiPaola et al 21 of PC-SPES is brief, but it does offer some specific clinical data. The review by Geliebter et al 22 is a brief but intense summary of the biological and clinical data on PC-SPES. Finally, Hawkins, 23 in a very brief review of a conference on Asian therapies for cancer, described aspects of PC-SPES including the list of contents and the in vitro, in vivo, and human studies.
Thus, the reviews have focused on the biological and clinical aspects of PC-SPES, in varying degrees of completeness and depth of analysis. None of the reviews addressed the botanical, chemical, biological, and clinical aspects of the product in an integrated manner. This summary will briefly examine these facets of the literature relating to PC-SPES and the issues that the product and its history raise in the large context of the dietary supplement industry.
Plant Materials in PC-SPES and Their Constituents
To begin to consider the diverse activities observed for PC-SPES, it is important to understand that there is a very substantial base of knowledge concerning each of the constituent plants in PC-SPES. Using the NAPRALERT database, 24 searches were conducted of the ethnomedical, biological, and chemical studies on each of the 8 plant materials indicated to be present in PC-SPES. Because of the immense volume of the literature involved, only a very brief summary (Table 1) can be presented here. The complete searches are available on request. Approximately 976 compounds have been identified to date from the plant materials in this mixture. Many more compounds remain to be characterized. Assuming some overlap between the 8 plants of some widely distributed compounds, there are undoubtedly at least 900 compounds present in each capsule at unknown concentrations. Some highlights of the previous chemical and biological studies on each of the plant constituents of PC-SPES follow.
I. indigotica I. indigotica is known in China as Banlangen or qing dai. The root part of the plant is present in PC-SPES. Both the roots and the leaves have been examined phytochemically. The dominant compound in the roots is the alkaloid indirubin (0.28%-0.51%), 25 along with the oxazolidine alkaloid epigoitrin (0.02%). 26 The material has been tested in China for the treatment of dacryocystitis and was more effective than tetracycline. 27 All of the previous phytochemical work was conducted in China. The closely related plant I. tinctoria is sometimes substituted for I. indigotica, and in fact they have the same names in traditional Chinese medicine (TCM) (some botanists view the 2 names as synonymous). The leaves of I. tinctoria have been studied in Germany (this is the source of the traditional dyestuff woad), whereas the roots have been studied in China, where they are used as an anticancer agent. 28 The roots of I. tinctoria have shown weak cytotoxicity, 29 and the active agent(s) is also thought to be indirubin. 30 G. glabra, Glycyrrhiza uralensis Fisch., and Glycyrrhiza inflata Batal.
Although the plant material listed as being a constituent of PC-SPES is the root material of G. glabra, the Chinese herbal drug gancao, Radix Glycyrrhizae, is also synonymous with G. inflata and G. uralensis. Known constituents of the 3 plant materials are somewhat similar; the main constituent of G. glabra is the triterpene saponin glycyrrhizin, first isolated in 1809 by Robiquet. 31 Very little phytochemical work has been done on G. inflata, and most on G. glabra. Distinctive phytochemical features between the species are a group of prenylated isoflavonoids in G. uralensis 32 and a group of 12,13-en-11-one triterpenes related to liquiritic acid (the sapogenin of glycyrrhizin) in G. glabra. 33 G. inflata has yielded triterpenes and flavonoids, with glycyrrhizin itself being the dominant principle, 34 along with isoliquiritin apioside. 35 The roots of Chinese licorice, also known as kanzo in Japan, as well as the roots of G. glabra, are estrogenic in mice, 36 are not cytotoxic, 37, 38 and do not have antitumor activity. 39 Several immune-stimulating polysaccharides have been isolated. [40] [41] [42] [43] Glycyrrhetic acid from G. glabra has shown mineralocorticoid-like effects 44 and inhibited the 5-beta reduction of cortisol, aldosterone, and testosterone. 45 Using a single high-performance liquid chromatography (HPLC) system, Kitagawa et al. 35 compared the flavonoid and saponin constituents of G. glabra, G. uralensis, and G. inflata from China. Total saponin content (based on 8 compounds) varied between 2.44% and 7.25%, and flavonoid content (also based on 8 compounds) varied between 0.07% and 2.10% for the 3 species. For G. uralensis, the flavonoid content varied between 0.07% and 0.29%. Thus, there is a need for standardization of the licorice (Glycyrrhiza species) being used in any botanical preparation. P. pseudoginseng var. notoginseng P. pseudoginseng is a complex species botanically, and the literature reports that 17 varieties and cultivars have been examined phytochemically; it is known as san qi in TCM. Extracts of the plant have not shown cytotoxic activity. 46 However, the antitumor activity of a polysaccharide fraction was patented in 1990. 47 Extracts have also shown anticarcinogenic activity, 48, 49 superoxide radical-scavenging activity, 50 and antioxidant activity. 51 The roots contain some of the well- Dendranthema morifolium  3  28  20  27  No known active compounds  1  0  0  0  Ganoderma lucidum  10  96  108  240  Polysaccharides have immune-stimulating  2  31  228  5+  and antitumor activity; triterpenes cytotoxic  Glycyrrhiza glabra  8  80  101  221  Polysaccharides have immune-stimulating  1  5  4  16  activity  Isatis indigotica  2  2  15  33 Indirubin, isatin † 0 0 0 0 ? Panax pseudoginseng var. 12 established ginsenosides of Panax ginseng CA Meyer (eg, Rb 1 , Rb 2 , Rg 1 , etc.), as well as some saponins, the notoginsenosides, which are unique to P. pseudoginseng var. notoginseng. 52 These representatives of the protopanaxadiol and protopanaxatriol types are used in the Chinese Pharmacopeia to distinguish notoginseng root from ginseng root. The principal use of the plant is as a hemostatic agent. Aspects of the quality control of ginseng products on sale in the United States have been studied at the University of Illinois at Chicago. 53, 54 G. lucidum Known in the Far East as reishi or ling zhi, the fruit body of the ganoderma mushroom has been well investigated for its extremely diverse biological properties. Among the many activities displayed by extracts of this drug are antitumor activity, [55] [56] [57] cytotoxic activity, 58, 59 immune stimulation, [60] [61] [62] DNA synthesis inhibition, 63 DNA polymerase beta inhibition, 64 lymphocyte proliferation stimulation, 65 natural killer cell enhancement, 66, 67 phagocytosis capacity increase, 68 and inhibition of tumor necrosis factor. 68, 69 The activities are typically associated with the complex polysaccharide fraction contained in the aqueous extract. However, recent reports indicate the presence of several triterpene derivatives that show cytotoxic activity on Meth-A and LLC cancer cells 70 and other triterpenes that are very cytotoxic to P-388, Hep G2, and HepG2,2,15 cells. 71 
D. morifolium
The dried flowers of D. morifolium collected in the fall are known as juhua. Flowers of the common chrysanthemum have been used to treat tumors in China. 28 No extracts of the leaves or flowers have shown activity in cell culture systems, and no active compounds have been isolated. Leaf samples from India produced contact dermatitis which may be because the closely related Chrysanthemum indicum L. (a misidentification?) contains sesquiterpene lactones, which C. morifolium does not. 72 This may be a useful way to standardize this plant compared with C. indicum.
S. baicalensis
The root of S. baicalensis is known in the West as skull cap, in China as huang qin, and in Japan as shosaikoto. It is widely used for bacterial infections of the respiratory and gastrointestinal tract. There is an ethnomedical report for the treatment of breast cancer 73 and a report for vaginal cancer as a component in a mixture with 6 other herbs. 74 Several reports vary on the cytotoxicity of the roots, although some cytotoxic flavonoids, for example, skulcapflavone II (5,2′-dihydroxy6,7,8,6′-tetramethoxyflavone), have been isolated. 75 An extract with 5 other herbs was tested in humans for anticancer activity and was not active, 76 but some activity was observed in animals. 77 Other related activities include DNA binding activity, 78 lymphocyte stimulation, 76 and white blood cell count stimulation. 79 Baicalein (6,7,8-trihydroxy-flavone) and wogonin 7-O -glucuronide are the dominant compounds, although estimates of the content of baicalein in the roots vary widely. 80, 81 Baicalein showed inhibitory activity on the conversion of fibrinogen to fibrin by thrombin 82 ; has antiproliferative, protein tyrosine kinase and lipoxygenase-inhibitory activity 83 ; and suppresses cell proliferation hepatoma cell lines. 84 The compound also inhibits topoisomerase II in human hepatocarcinoma cell lines 8 5 , 8 6 and cAMP phosphodiesterase. 87 Baicalein and other derivatives from Scutellaria were shown to possess antimutagenic activity 88, 89 and, in a mouse tumor model, to suppress skin tumor promotion. 78, 90 Baicalein itself inhibits TPAinduced epidermal ornithine decarboxylase activity. 91 At 7 µg/mL, baicalein arrests LNCaP and JCA-1 prostate cancer cells in the G 1 phase and decreases androgen receptor expression. 92 The androgen-negative JCA-1 cells were slightly more sensitive to both baicalin and baicalein. Both compounds also decreased androgen receptor expression in the cytoplasm and the nucleus of LNCaP cells. Earlier studies 9 3 had demonstrated that baicalin (baicalein-7-β-Dglucuronide) inhibited the growth of several human prostate cancer cell lines (DU145, PC-3, LNCaP, and CA-HPV-10), albeit at doses that were quite high (~200 µM). LNCaP and PC-3 cells were the most resistant. Baicalin caused DNA fragmentation, activation of capsase-3, and cleavage of poly-ADP-ribose polymerase. 93 The activation of capsases, an evolutionarily conserved family of cell death proteases, is recognized as an important aspect in developing effective prostate cancer therapy, 94 and these enzymes are therefore an important drug target. It is worth mentioning that of the 228 compounds isolated from the plant, 215 have been isolated from the roots, and of these, 102 are flavonoids.
R. rubescens
The root portion of R. rubescens is present in PC-SPES. Several species of Rabdosia are used in China for antitumor or anti-inflammatory agents, and there are numerous phytochemical studies demonstrating that unsaturated labdane diterpenes are responsible for this activity. 31 A decoction of the leaves of R. rubescens is used in China for the treatment of esophageal cancer. 95 An extract showed cytotoxic activity in a human ovarian cancer cell line (ED 50 0.58 µg/mL), 96 and an ethanolic extract showed cytotoxicity against CA-ECA-109 and HeLa cells. 9 7 Rubescensine 9 8 and rubescensine B 99 were isolated as cytotoxic constituents of the leaves. There are no phytochemical or biological reports on the roots of this plant.
S. repens
Known also as saw palmetto, S. repens is the only Western plant in the PC-SPES mixture. Now widely used as a phytotherapeutic agent for benign prostatic hyperplasia, the fruits of saw palmetto have a wide range of biological activities, although no bioactive compounds have been isolated. Ethnomedically, saw palmetto is claimed to be useful as an estrogen 100 and for prostate inflammation, 101 and its effects on benign prostatic hyperplasia have been reviewed. 102 The estrogenic effects have been confirmed on a methanol extract, 103 whereas androgenic effects in castrated rats have been observed for a supercritical fluid extract. 104 This extract consisted mostly of fatty acids (93.5%) and 0.22% beta-sitosterol. Permixon ® , a hexane extract of saw palmetto, shows inhibition of type I and II isoenzymes of 5α-reductase at 10 µg/mL without influencing the secretion of PSA by epithelial cells. 105 It should be noted that finasteride only inhibits the type II isozyme, but at a dose of 1 ng/mL. 106 Earlier work had shown the inhibition of 5α-reductase by the free fatty acid fraction of saw palmetto. 107 A sterol fraction has shown antiandrogenic effects in humans 108 and cell systems. 109 The sterol fraction has also shown cytotoxic activity against PC-3 and LNCaP cell lines. 109 Beta-sitosterol has been implicated as an active principle 100, 103 through studies of uterine weight as a percentage of body weight in female mice, but this seems somewhat unlikely because the compound is ubiquitous in plants and is available in much higher levels from different plant sources. The whole plant extract showed significantly greater activity, 110 suggesting that other estrogenic principles are present. In an in vitro comparison with finasteride, several extracts of saw palmetto, Pygeum africanum Hook.f. (Rosaceae), and Urtica dioica L. (Moraceae) were evaluated for their effects on human prostatic 5α-reductase, and only Permixon and Talso ® (another saw palmetto extract) showed weak activity. In humans, Permixon showed no effect on the reduction of serum dihydrotestosterone levels. 110 A clinical trial in benign prostatic hyperplasia sponsored by the National Institutes of Health is presently being established.
Summary
There are almost no detailed published studies of the chemical nature of PC-SPES. One report suggests that baicalein represents 10% of the total ethanolic extract of PC-SPES, 92 and it was suggested that at the observed concentration, this compound could not account for all of the observed activities.
Biological Evaluation
The profound estrogenic side effects observed in patients taking PC-SPES indicate the presence of a compound, or series of compounds, with estrogenic activity in 1 or more of the 8 plant materials present in the mixture. Of the 8 plants in the mixture, only 4 have been tested for their estrogenic activity. Two of these, P. Pseudoginseng var. notoginseng and S. baicalensis, were part of a multicomponent mixture that was found to display estrogenic activity in human females. Indeed, the preparation is used in TCM to treat functional uterine hemorrhage. 111 An ethanolic extract of G. uralensis showed estrogenic effects in mice, with activity being variable depending on the season. 36 At 2.5 mg/animal, a methanolic extract of the fruits of S. repens had estrogenic activity in infant mice. 103 In no instance has the estrogenic activity been traced to an active compound or series of compounds.
The role of estrogens in the control of prostate cancer is of great interest. Diethylstilbestrol (DES) has been shown to induce apoptosis in hormoneinsensitive prostate cancer cells (DU145, 1-LN, and PC-3), resulting in cells accumulating in the G 2 /M phase. 112 In androgen-sensitive cells (LNCaP), no such accumulation occurred, although cytotoxicity was observed. DES has been used in the treatment of advanced human prostate cancer. 113, 114 There are several published reports examining the biological effects of PC-SPES in vitro. In initial studies, it was claimed that an alcoholic extract of PC-SPES was cytotoxic to hepatoma cells and suppressed the growth of Bel 7402 hepatoma in nude mice. 115 Subsequently, Wu and colleagues 116 examined the effects of an extract of PC-SPES on LNCaP cells. Proliferation was decreased and was accompanied by 60% to 70% down-regulation of the proliferating cell nuclear antigen (PCNA) and level of secreted PSA. It also suppressed 5α-reductase expression in LNCaP cells. Wu and colleagues 117 followed this with a study of the effects of PC-SPES in Mutu cells, which are abundant in bcl-6, a protooncogene that may function as a transcriptional repressor 118 in lymphoma tumorigenesis. 119 Ethanolic extracts of PC-SPES caused a dose-dependent reduction of bcl-6, whereas actin levels remained unchanged over a 7-day period (at 1 and 5 µg/mL). There were also no changes observed in the phosphorylated and unphosphorylated forms of the retinoblastoma gene RB. 117 More detailed in vitro studies were conducted by Darzynkiewicz and colleagues. 120 They found broad activity of a PC-SPES extract in the proliferation of PC-3 and LNCaP prostate carcinomas, MCF-7 and T47-D breast carcinomas, SK-N-MC neuroepithelioma, Colo 38 melanoma, U-937 histiomonocytic lymphoma, and HL-60 and MOLT-4 leukemia cells. MCF-7 cells were the most sensitive, and no dependency on estrogen or androgen receptors was noted. Typically cells accumulated in the G 1 phase, although PC-3 cells were arrested in the G 2 /M phase. In the U-937 cells, downregulated expression of bcl-2, the gene responsible for protecting cells against apoptosis, was observed. Expression of bcl-2 in endometrial cancer is also downregulated by estradiol. 121 These effects were further studied by Koeffler and colleagues. 122 After diluting 1 capsule of PC-SPES (320 mg) in 1 mL of 70% ethanol, they found that at 2 µL/ mL, clonal growth of LNCaP, PC-3, and DU 145 prostate cancer cells was inhibited 50%. There was a concomitant increase of cells in the G 1 (LNCaP and PC-3 cells) or G 2 /M (DU 145 cells) phases. At the same dose, there was a 40% decrease in bcl-2 expression in PC-3 cells, but the levels of p27 kipl , E-cadherin, and telomerase were unchanged. de la Taille et al 123 DiPaola et al 125 examined the estrogenic effects of PC-SPES using transcriptional activation assays in yeast and in ovariectomized CD-1 mice. In yeast assays, a 1:200 dilution of an ethanol extract of PC-SPES had estrogenic effects similar to that of 1 nM estradiol, and in mice the extract increased uterine weights substantially.
Mittelman and colleagues 126 reported on the antitumor effects of PC-SPES in prostate cancer using the Dunning R3327 rat model. It was shown that PC-SPES had a dose-dependent effect on the highly metastatic prostate cancer cell line MAT-Ly-Lu at 500 mg/ kg/day, wherein both tumor incidence and tumor volume were decreased by about 43%. At a level of 0.05% of the diet, metastasis to the lungs was also reduced.
Koeffler and colleagues 122 also examined the effects of PC-SPES in vivo. At 250 mg/kg/day given orally, PC-SPES reduced the tumor weights and tumor volume of androgen-independent DU 145 cells in mice by almost 50% after 8 weeks. Limited effects were noted on PC-3 cells in vivo. When administered at the time of tumor implantation, de la Taille et al 124 found that PC-SPES reduced tumor volume, nonstatistically significantly, in immunodeficient mice with PC-3 cell line xenografts after 2 months.
One of the components in PC-SPES is licorice root, and one of the constituents, the chalcone licochalcone-A (LA), was examined by DiPaola and colleagues. 127 LA was already known to inhibit tumor promotion 128 and to have antileishmanial activity. 129 In yeast PL3 cells, both LA and genistein at 50 µM supported growth. LA decreased the viability of MCF-7, PC-3, and DUPro-1 tumor cells at 20 µM, and at 1 µM also enhanced the cytotoxicity of vinblastine and paclitaxel. In MCF-7 cells, bcl-2 expression was decreased by LA but not by estradiol. 127 PC-SPES showed similar levels of cytotoxic activity against drug-sensitive (H69) and multidrug-resistant (H69VP) small-cell lung carcinoma cells. 130 
TUNEL analysis indicated that apoptosis had occurred.
A recent study addressed the core issue of which of the plant materials in the product might be responsible for any of the activities observed. Hsieh and Wu 131 evaluated extracts of the 8 plant materials at 1 µg/mL and 5 µg/mL against androgen-dependent prostate cancer (LNCaP) cells. At 5 µg/mL, the reduction of growth suppression was 85.2% for D. morifolium, 80.9% for P. pseudoginseng var. notoginseng, 73% for G. uralensis, 70.8% for R. rubescens, 66.5% for S. baicalensis, 63.5% for G. lucidum, 50.0% for I. indigotica, and 14.5% for S. repens. At 1 µg/mL, only D. morifolium and P. pseudoginseng var. notoginseng inhibited more than 50% of the cell growth. Three plant extracts were shown to lower intracellular and secreted PSA, namely, G. uralensis, S. baicalensis, and S. repens. The other plants actually increased PSA expression. No coordinated response was found from the individual plant extracts in an evaluation of intracellular androgen expression and PSA levels, although the extract of PC-SPES down-regulated PSA expression and reduced the level of the androgen receptor. 17 The extracts were also evaluated for their ability to down-regulate the expression of estrogen receptor ER-α; 4 plant extracts were active, P. pseudoginseng var. notoginseng, R. rubescens, G. lucidum, and S. repens. ER-α is important because it has been shown to increase during the progression of prostate cancer. 132, 133 Although it advances knowledge of the individual plant materials substantially, the study 131 also suffers from the lack of positive identification of the plant materials and a lack of confirmation of the absence of contamination or adulteration.
Clinical Reports
The early anecdotal evidence from Taiwan was that the product reduced a prostate cancer patient's PSA level to less than 1 ng/mL after 5 years. Subsequently, Moyad et al 134 reported a patient with a PSA level of 8.8 ng/mL treated with 9 capsules of PC-SPES per day whose PSA level dropped to 0.1 ng/mL after 8 weeks, but who experienced pronounced gynecomastia and hair loss. A Man to Man support group located in Syracuse, New York, collected anecdotal reports from several members, which included clinically documented changes of PSA levels and Gleason levels and effects on tumor progression. The following are representative experiences of patients, collected by the group: PSA dropped from 7.6 to 3.7 in 7 weeks; PSA of 6.8 and no other therapy changed to PSA of 1 after 2 months with no disseminated cancer; postoperative PSA of 0.9 rose to 10.5 and fell in 2 months with PC-SPES to 0.07 (many side effects noted); PSA of 55, with hormone therapy, failed after about 3 years; PSA of 41.9 dropped to 31 after 1 month on PC-SPES; PSA of 20.7 was reduced to 1.3 after 3 weeks on PC-SPES; PSA of 136 following radiation treatment, surgery, and several different hormone therapies, reduced to 37.2 after 8 months on PC-SPES; patient following radical prostatectomy had PSA level of 47.2 that dropped to 15.1 after 1 month and 0.49 after 5 months on PC-SPES.
Much of the information relating to the clinical aspects of the use of PC-SPES is anecdotal and relates to commentary on the Internet or in response to support group surveys that validates the substantial decrease in serum PSA levels following regular use of the product. In 1997, the group UsToo surveyed a sample of members 135 and repeated this study in mid 1999 with 56 usable responses from the original cohort of 82 men. 136 About half (48%) of the respondents were taking 6 to 9 capsules per day, and 2 of the most dominant side effects (68%) of respondents were breast tenderness (40% in the first survey) and leg cramps (9%; 3% in the first survey). Positive results, in terms of lowering PSA levels, were observed in 93% of those surveyed.
de la Taille et al. 137 reported on 2 cases of prostate cancer patients with metastatic disease treated with total androgen blockade. Treatment was with 3 capsules of PC-SPES a day in one case and 6 capsules a day in the other. Their initial values of 100 and 386 ng/mL were reduced to 24 and 114 ng/mL after 1 year and 4 months, respectively. No gynecomastia was observed in these patients.
In a case report, Loblaw and colleagues 138 described a patient who, after a short period on PC-SPES, developed disseminated intravascular coagulation. The report suggested PC-SPES as the principal cause, since the bleeding stopped after discontinuing PC-SPES.
Clinical Studies
In the limited clinical studies that have been conducted in somewhat controlled environments, the ability of PC-SPES to lower PSA levels is the effect that has been used as a measurable marker by clinicians. In a phase II study of 60 men in 2 equal treatment (9 capsules per day) groups by Kameda et al., 139 the response rate for a 50% reduction in serum PSA level was 75% for hormone-naive and also for androgen-independent prostate cancer. Pfeifer et al 140 reported on a trial involving 16 men (49 to 77 years old) with advanced metastatic prostate cancer (stage D3). After hormone ablative therapy had failed, all patients received PC-SPES (9 capsules per day) for 5 months. Significant improvements were noted in quality-of-life measures, reductions in pain ratings, and decline in PSA levels, with a 40% drop in level being typical after 8 weeks, followed by a plateau. Pfeifer et al. 140 commented on the lowering of pain observed with PC-SPES and attributed the activity to G. glabra, G. lucidum, R. rubescens, and P. pseudoginseng var. notoginseng. The effects led to better ambulation, more energy, and increased appetite.
A very high response rates for reducing PSA levels had also been observed by DiPaola et al 125 in 8 of 8 patients and by de la Taille et al 123 in 27 of 33 (87%) patients after 1 and 2 months, respectively. PSA levels were lower in 87% of 33 patients after 2 months and in 78% of patients at 6 months (n = 18, P = .026). DiPaola et al 21 reported on a group of 8 men receiving PC-SPES. Decreased serum PSA levels were observed in all of the men, and testosterone levels (in 6 of 6 men) were reduced dramatically. The range of reduction of PSA levels was quite variable, from 122 down to 1.2 ng/mL in one patient and from 6.7 to 5.6 ng/mL in another patient. It was concluded that PC-SPES had potent estrogenic activity.
More detailed clinical studies have been reported by Small et al. 141 in 70 patients; 33 with androgendependent prostate cancer and 37 with androgenindependent prostate cancer. For those with androgendependent disease, PSA levels declined by greater than 80% in 100% of the men. Undetectable levels were reported in 81% of patients. No disease progression occurred at a median follow-up of 59 weeks. Ninetyseven percent of patients developed anorchid levels of testosterone after 8 weeks on PC-SPES. Some patients with no prior therapy experienced a reduction in the size of the prostate (androgen deprivation), suggesting an antiproliferative effect. All patients in the androgen-dependent group experienced a loss of libido. The estrogenic effects were also seen in the side effects of gynecomastia or gynecodynia in 100% of the hormone-naive patients, although hot flushes were also seen in about one third of these patients. For the androgen-independent prostate cancer group, PSA levels declined by more than 50% in 54% of patients with a duration of 4.5 months. Interestingly, given subsequent events, these effects are quite similar to those observed previously by Smith et al. 142 for the effects of DES in a similar group of 21 patients.
de la Taille et al 124 reported on a group of 69 patients receiving PC-SPES who had received prior cryotherapy, radiation therapy, hormone therapy, and/or radical prostatectomy; 22 patients after hormone therapy; and 4 patients with no prior therapy. After a mean follow-up of 8.5 months, no patients had overt disease progression. After 2 months, 82% of patients had decreased serum PSA, and at 6 months, 74% of the hormone refractory patients had decreased PSA levels. In this study, 42% of patients experienced nipple tenderness and 8% had gynecomastia.
Oh et al 143 evaluated 23 patients with androgenindependent prostate cancer following treatment with 6 capsules per day. A decline in PSA level was observed in 87% of patients, with a median decline of 40%; the median duration of the response was 2.5 months.
Common side effects of PC-SPES include loss of libido and potency, gynecomastia, and gynecodynia, which are commonly observed with estrogen therapy. 141 Also observed in this study were mild leg cramps (68%), diarrhea (39%), and, in 6 (8.6%) cases, cardiovascular or thromboembolic events. It was recognized that a prior history of cardiovascular disease would suggest that PC-SPES not be used. In the study of Oh et al, 143 which employed a lower dose of PC-SPES (6 capsules per day), nipple tenderness (34.8%), nausea and vomiting (21.7%), gynecomastia (8.7%), and leg cramps or swelling (8.7%) were observed. The venous thrombotic events were also noted by DiPaola et al 125 and de la Taille et al 124 and are a known complication of estrogen therapy. 144 In a case report, 145 the interaction of warfarin and PC-SPES was evaluated, with the result that the combined use excessively prolongs the international normalized ratio. Removing the patient from PC-SPES led to a rise in PSA level, and thus PC-SPES was added back into the regimen whereas the Coumadin ® dose was reduced. Oh et al 146 reported on the change in PSA levels in 4 cases in which PC-SPES was withdrawn. In 3 instances, a rapid rise in PSA level was noted after prolonged low to moderate levels upon withdrawal of PC-SPES. In the fourth case, the PSA level rose upon withdrawal and then was restored to a low level upon adding PC-SPES back into the regimen. Increases in PSA level were in the range of 345% to 880% in 1 month in the 4 cases. Patients typically also experienced a reduction in pain while on PC-SPES.
A case of bleeding diathesis related to PC-SPES has also been reported. 147 The patient was taking 12 capsules of PC-SPES per day and presented with a prothrombin time of > 106 seconds and a platelet count of 629,000/mm 3 . Following transfusion, after 21 days, the prothrombin time returned to normal (12.1 seconds) and the activated partial thromboplastin time, which had risen to > 120 seconds on admission, was reduced to 25 seconds. Interestingly, clinical analysis revealed a plasma warfarin level of 0.69 µg/mL (below the therapeutic range of 2 to 8 µg/mL), which, however, was reproducible upon administration of PC-SPES to mice after 3 days of dosing. 147
Withdrawal of PC-SPES From the Marketplace
The withdrawal of PC-SPES from the marketplace in January 2002 occurred after the wife of a patient acquired, and arranged to have chemically examined, a number of samples of an older preparation of PC-SPES and a new sample. The laboratory found that the older samples contained low levels of DES. In August 2001, a second laboratory confirmed these findings. In early September, BotanicLab issued a recall of 2 of the older batches of PC-SPES. More recently, in January 2002, the 2 federally sponsored clinical trials of the product, by Small's group and Oh's group, were stopped. This occurred after Small's group found DES in some of the 4 trial lots of PC-SPES. At the time the trial was halted, according to the PSA Rising Web site (www.psarising.org), there was a substantial difference in the decline of PSA levels by 50% or more between the PC-SPES group (45%) compared to the control group (21%). Given the failure of other laboratories to find DES in PC-SPES, this remains a somewhat controversial issue.
Also in January 2002, the California Department of Health Services reported that in the newer batches of PC-SPES, warfarin, an anticoagulant, was present at a level of 0.211 mg/capsule (www.dhs.ca.gov). At the frequently used dose of 9 capsules/day, this represents 1.9 mg/day, approximating the lowest recommended maintenance dose. Recall that one of the side effects of PC-SPES (and DES) is blood clots, particularly in the lower limbs. 124, 125, 147 BotanicLab issued a recall for all lots of PC-SPES on February 8, 2002 . The FDA also posted a notice with regard to PC-SPES on its Medwatch Web site (www.fda.gov/medwatch/safety/ 2002/safety02.htm#spes). BotanicLab, while denying knowledge of adulteration, has countered with a 6month program for the improvement of its quality control procedures. Previously, these procedures were completely outside of its control because the product was being manufactured in China. The company also indicated that it will "confer with the scientific community as to how the herbs used in manufacturing PC-SPES can interact with each other over time" (www.botaniclab.com). The inference appears to be that warfarin and DES are natural products. Standard long-term stability studies should have established this before marketing. The mix of a prescription product (Coumadin ® in this case) and a nonregulated dietary sapplement is illegal in the United States, and thus physicians are advising all patients to cease using the product.
Comments
The federal government had invested substantial funds in the initiation of clinical trials of PC-SPES, in part because the product was very well regarded in the CAM community. However, as the debacle of the constitution of PC-SPES unfolds, in addition to the emotional and clinical impact for consumers and their families of the withdrawal of the product from the marketplace, 2 critical aspects of the clinical trials of phytotherapeuticals resonate. These issues are fundamental for the clinical trial of any drug or device, but for some reason are often overlooked or ignored when phytotherapeuticals are being evaluated. They are the quality and the reproducibility of the material being evaluated. It is inappropriate, indeed in my view it is unethical, to acquire a commercial product and administer it directly to humans in any clinical trial without any independent knowledge as to the nature of the material that is actually being delivered to the patient.
Thus, the crucial question in this scenario is, What controls were in place to ensure the quality of the PC-SPES being clinically evaluated from a botanical, chemical, and biological perspective? Was the material analyzed in any way prior to the clinical trial for authenticity, heavy metal contamination, pesticide and insecticide contamination, microbial contamination, radiation level, synthetic drug adulteration, contamination with other plant materials, and long-term stability and shelf life? Undoubtedly, these fundamental aspects of quality control and protection of human subjects were ignored. How could a federally sponsored clinical trial have failed to establish these minimal standards for such a product? How could such a clinical trial pass a local institutional review board? It is axiomatic that such trials must have a solid foundation in botany, chemistry, and biology before they are initiated.
The World Health Assembly, recognizing that plant materials are used as traditional remedies, over-thecounter drug products, dietary supplements, and raw materials in all countries of the world, through its resolutions WHA31. 33 (1978) , WHA40. 33 (1987) , and WHA 42.43 (1989) , has emphasized the importance of modern control methods for medicinal plant quality. In 1998, the World Health Organization published a monograph discussing the need for such standards and describing the methods to be used for the determination of more than 15 factors related to the establishment of a plant material as being noncontaminated. 148 It was recognized that these methods could be extended and expanded through more sophisticated techniques (HPLC, mass spectrometry, nuclear magnetic resonance, or various hyphenated techniques), depending on the level of technology available.
It is disturbing that the parties involved in approving the trials did not recognize the essential need and their responsibility to conduct the necessary botanical, chemical, and biological studies on this poorly described mixture, PC-SPES, prior to initiating the clinical studies. The result is a serious blow to those research centers establishing the protocols for the clinical trials of other phytotherapeuticals, and it undermines general consumer confidence in the labeling of dietary supplements. This apparent lack of concern diminishes the role of botanists, pharmacognosists, natural product chemists, biologists, pharmacologists, and other scientists in establishing the scientific foundation on which to base the clinical trial of a phytotherapeutical. It is essential that such scientific areas be represented on the National Center for Complementary and Alternative Medicine (NCCAM) Scientific Advisory Board, as well as in the various review groups responsible for evaluating clinical trial proposals for dietary supplements.
The previous lack of concern of BotanicLab about its product is also very alarming and has to be a lesson in science and ethical priorities to the whole dietary supplement industry. The company failed to reach out to the natural product scientific community for assistance in establishing the identity of its product several years ago. Instead, it chose to rely on its supplier in the People's Republic of China and, apparently, never attempted to verify that the materials were authentic and unadulterated on a batch-to-batch basis. As a result, the reputation of a whole industry has been sullied in the mind of the general public. Although it is true that no deaths resulted directly from this negligence, it is also true that some prostate cancer patients will probably not live as long as they might have if PC-SPES was authenticated, free of side effects, effective, and still on the market.
Future Concerns
As Cordell [149] [150] [151] has indicated previously, new standards of fundamental practice for quality control in the herbal industry are long overdue. For too long the balance of the money equation has been on the side of profit and not science; on marketing and not efficacy; on fiction and not reality. Consumers have been consistently led to believe 2 myths: (1) that natural products are safe and (2) that the quality of the products is in some way regulated by the federal government. When these myths are exposed, as has occurred with PC-SPES, consumers rightly feel betrayed by the parties concerned.
In January 2000, the FDA Center for Food Safety and Applied Nutrition (CFSAN) developed a 10-year plan for "a science-based regulatory program that fully implements the Dietary Supplement Health and Education Act of 1994, thereby providing consumers with a high level of confidence in the safety, composition and labeling of dietary supplement products." 152 Working with limited resources, the CFSAN developed a list of points to be addressed annually over the period. Implementation of this plan, such as the issuance of good manufacturing practices, the plan's second objective, may assure that consumers are more protected from a safety perspective. However, the overall plan does not begin to track the pathway, which the NCCAM is starting to follow, of establishing standards that relate to the determination of product efficacy. It is clearly in the public interest that this discontinuity of purpose be resolved quickly. In August 2000, the FDA Center for Drug Evaluation and Research published new draft guidance for botanical products relating to what would be needed for investigational drug applications to begin phase 1 and phase 2 clinical trials. 153 Whether the application of these guidelines would have been effective in clarifying the material content of PC-SPES prior to the initiation of the clinical trials is a matter of speculation.
As has been suggested previously by a number of leaders in the pharmacognosy community, the time is propitious for the FDA, the Federal Trade Commission, the NCCAM, the Office of Dietary Supplements, the dietary supplement industry, the United States Pharmacopoeia, concerned consumer groups, and the respective scientific organizations to work together on a 15-year plan to establish exacting standards (substantially beyond those of good manufacturing practices and a site inspection program) for the sale of all phytotherapeutical agents in the United States. It is time for the adoption of regulations, in harmony with standards established elsewhere in the world, mandating the safety, quality, and efficacy of dietary supplements from the field to postmarket surveillance. The public certainly deserves, and should demand, no less.
Future Research on PC-SPES
And what is the future for PC-SPES? PC-SPES is an uncharacterized botanical product. Our preliminary research using HPLC-electrospray mass spectrometry indicates that it may be almost uncharacterizable. The label indicates that the product contains 8 herbs.
There is no independent evidence for this. The content (proportion) of each herb in the preparation is not given. The herbs are listed on the label in alphabetical order. Does this reflect their relative proportions in the product? Are those proportions consistent on a batch-to-batch basis? Is the identity, quality, and biological activity of each of the individual components established prior to inclusion in the product? We will probably never know.
PC-SPES appears to have a number of significant biological effects, including cytotoxic activity in several prostate and other cancer cell lines, apoptosis in both hormone-sensitive and hormone-insensitive prostate cell lines, down-regulation of the bcl-2 gene, down-regulation of PCNA, reduction in secreted PSA, suppression of 5α-reductase, reduction in levels of the bcl-6 gene, estrogenic effects in a yeast assay and in mice, and dose-dependent antitumor effects against prostate cancer in both rat and mouse models. Clinically, the supplement at 9 capsules per day substantially reduces PSA levels over a 1-to 2-month period and, apparently, suspends disease progression for several months. PC-SPES can also cause estrogenic effects (breast tenderness, breast enlargement, and leg cramps). Testosterone levels are reduced substantially, libido is reduced, and erectile dysfunction may occur. Some pain lowering has been noted by some patients, together with extensions in prothrombin time.
This suggests that several of the constituents in the complex mixture of secondary metabolites in PC-SPES may modulate the regulation of a number of different cellular targets. Correspondingly, these compounds may act in either a synergistic or an antagonistic manner in combination with other drugs and therapeutic modalities, such as radiation. Quantitating and reproducing those effects in a systematic manner is important in order to optimize the utility of PC-SPES and/or associated products. According to Darzynkiewicz et al, 17 "The critical point for the future use of PC-SPES by prostate cancer patients is quality assurance from the manufacturer (p734)." These authors also suggested "that the manufacturer includes the HPLC fingerprint for each batch of PC-SPES . . . and that a biological test be developed to assess the potency of individual batches (p734)." They omitted to point out that such information would have been critical in adding credibility to the chemical, biological, and clinical data, including their own, obtained on the previous batches of PC-SPES.
The chemical, biological, and clinical studies conducted thus far with PC-SPES, with 1 exception, 131 typically reflect a lack of appreciation of the complexities of studying multicomponent, biologically active plant materials. In almost all of the reports to date, the marketed product has only been evaluated biologically, not botanically or chemically. Batch numbers of the PC-SPES being evaluated are never cited. None of the prior studies, including the clinical studies, has examined the marketed product in order to determine whether the plant materials claimed to be present are indeed present, or whether the potential active principle(s) can be isolated using bio activity-directed fractionation. Consequently, almost all of the previous biological and clinical studies are of almost no value given the issues that have emerged related to the highly probable adulteration of the samples. There is now a need to be able to separate the activities due to the adulterants from the activities that might be present due to the constituents of the plant materials.
The previous studies have not examined any individual or combination of the plant extracts for their bioactivities as estrogenic, 5α-reductase inhibitory, and bcl-2-, bcl-6-, and PSA-modulating agents. Only 1 study 131 has evaluated the individual plant materials contained in the product in a cytotoxicity assay. No investigations have focused on which compound(s) might be used as biomarkers to assess chemical and biological consistency. No efforts have been made to maintain or improve efficacy and reduce the doselimiting toxicities. There is no evidence that all 8 plant materials are either necessary or desirable for efficacy. The optimum formulation, dose, duration, and schedule for PC-SPES have not been determined. The efficacy profile remains unclear on a patient-to-patient basis. The methods of standardization used by the company are unknown. The stability of the product remains unknown. Contraindications and important drug-herb interactions are not known. As a result, development of a long-range plan to investigate the observed clinical efficacy of the product is made substantially more difficult. Yet, that is precisely what is called for.
